What is Metrion Biosciences?
Metrion Biosciences operates as a specialized contract research organization (CRO) dedicated to providing high-quality preclinical drug discovery services. The company's core expertise lies in ion channel screening, cardiac safety, and neuroscience, offering a comprehensive suite of services including high-throughput screening and GLP hERG testing. By delivering expert advice, reliable data, and tailored solutions, Metrion empowers pharmaceutical and biotech companies to overcome complex drug discovery challenges and accelerate their research and development pipelines.
How much funding has Metrion Biosciences raised?
Metrion Biosciences has raised a total of $14.2M across 4 funding rounds:
Grant
$2.5M
Series B
$3.7M
Unspecified
$3.7M
Private Equity
$4.4M
Grant (2016): $2.5M, investors not publicly disclosed
Series B (2021): $3.7M led by Gresham House Asset Management
Unspecified (2021): $3.7M supported by Gresham House Ventures
Private Equity (2023): $4.4M featuring Maven Capital Partners UK and Gresham House Ventures
Key Investors in Metrion Biosciences
Maven Capital Partners UK
Maven Capital Partners UK LLP is a venture capital and private equity firm that invests in companies across various sectors. Their involvement suggests a strategic interest in Metrion Biosciences' growth and operational scaling.
Gresham House Ventures
Gresham House Ventures is an investment firm that typically backs companies with high growth potential. Their continued participation indicates a strong belief in Metrion Biosciences' business model and market position.
Gresham House Asset Management
Gresham House plc is an asset manager with expertise in alternative investments, including private equity. Their backing of Metrion Biosciences highlights the company's strategic importance and potential for significant returns.
What's next for Metrion Biosciences?
The recent major strategic investment in Metrion Biosciences suggests a strong market confidence in its specialized drug discovery services, particularly within the ion channel and neuroscience sectors. This capital infusion is likely to fuel further expansion of its service offerings, investment in advanced screening technologies, and potentially broaden its client base. The company's focus on critical preclinical services positions it to capitalize on the ongoing demand for efficient and effective drug development solutions, indicating a trajectory of sustained growth and innovation in the competitive CRO landscape.
See full Metrion Biosciences company page
